Close Menu

NEW YORK – Exact Sciences has received a letter from the US Food and Drug Administration granting it Emergency Use Authorization for an in vitro diagnostic assay for the detection of SARS-CoV-2.

The SARS-CoV-2 RT-PCR assay test, which will be performed at Exact's CLIA-certified lab, is a real-time PCR assay intended for the qualitative detection of the virus' nucleic acids in nasal, nasopharyngeal, and oropharyngeal patient swabs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.